Pablo Lapuerta

A Randomized, Double‐Blind, Placebo‐Controlled Phase 1 Study of Adiponectin Agonist ( PEG )‐ BHD1028 in People With Insulin Resistance

Pablo Lapuerta, Brian B. Kim

, HOMA-IR ≥ 1.8, and HbA1c < 6.5% received subcutaneous injections of (PEG)-BHD1028 or placebo in single-ascending dose (SAD) cohorts (4, 8, 16, 32, and 64 μg/kg) and multiple-ascending dose (MAD) cohorts for 28 days (8, 16, and 32 μg/kg QD). Each …

us (code pays fourni par la source)

466. Advancing Novel Small Molecule Glycogen Synthase Kinase 3β (GSK3β) Inhibitors for the Treatment of Bipolar Disorder: Pre-Clinical Target Engagement

Sarina Mohanty, Pablo Lapuerta, Stephen Haggarty

us (code pays fourni par la source)

878-P: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of Adiponectin Agonist (PEG)-BHD1028 in Subjects with Insulin Resistance

Pablo Lapuerta, Brian W. Kim

Introduction and Objective: Low adiponectin levels may contribute to insulin resistance. This first-in-human study evaluated adiponectin receptor agonist (PEG)-BHD1028 in subjects with insulin resistance. Methods: Adults with BMI ≥27 kg/m2, HOMA-IR ≥ 1.8, and HbA1c < 6.5% received subcutaneous injections of (PEG)-BHD1028 …

us (code pays fourni par la source)

Randomized Phase Ib Clinical Trial of DB-020 Intratympanic Injections to Reduce High-Dose Cisplatin Ototoxicity

Benedict James Panizza, Stephen John O’Leary, Christopher David Hart, Chandra Sai Diwakarla et autres

PURPOSE This study evaluated DB-020, a formulation of thiosulfate for intratympanic (IT) injection, in patients receiving high-dose cisplatin chemotherapy. METHODS This randomized phase Ib clinical trial enrolled patients older than 18 years from five centers in Australia and the United States scheduled …

au, us (code pays fourni par la source)

A phase 1 clinical trial of DB-020 intratympanic injections administered prior to high-dose cisplatin chemotherapy to reduce ototoxicity.

Benedict James Panizza, Stephen John O’Leary, Christopher David Hart, Chandra Sai Diwakarla et autres

6100 Background: Hearing loss (HL) as a result of cisplatin (CP) chemotherapy is common. DB-020 is a formulation of sodium thiosulfate for intratympanic (IT) injection being developed to reduce CP ototoxicity. This phase 1 study was designed to evaluate safety and tolerability …

au, us (code pays fourni par la source)

Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone

Thomas Danne, Matthew D. Reaney, Philip Banks, Marion Afonso et autres

Background: Diabetes-related distress is common among persons affected by diabetes and is associated with suboptimal glycemic control and complications, thus constituting a relevant patient-report outcome (PRO). Improving glycemic control may reduce diabetes distress and improve treatment satisfaction. This post hoc analysis evaluated …

us (code pays fourni par la source)

129. The Effects of Novel Small Molecules in a Preclinical Model of Positive Affective State

Sarina Mohanty, Amanda J. Roberts, Daniel Lévy, Stephen J. Haggarty et autres

us (code pays fourni par la source)

A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin

Pablo Lapuerta, Silvia Urbina, Jiaojuan He, Alyssa Wittle et autres

YG1699 is a novel inhibitor of sodium‐glucose cotransporter 1 (SGLT1) and SGLT2. This double‐blind, 3‐way crossover trial compared YG1699 to dapagliflozin as an adjunct to insulin in people with type 1 diabetes (T1D) on insulin pump therapy. Treatment periods included four mixed …

us (code pays fourni par la source)

883-P: Effects of YG1699 and Sotagliflozin on Blood Glucose and Urinary Glucose Excretion in SD Rats

JACKY LI, ROGER W. XU, JIAOJUAN HE, Pablo Lapuerta

Background and Aims: YG1699, a dual inhibitor of SGLT1 and SGLT2, recently showed greater glucose lowering than dapagliflozin in patients with type 1 diabetes. This study examined the potential mechanism of glucose reduction in rats. Materials and methods: Sprague Dawley rats received …

882-P: Effects of YG1699 and Sotagliflozin on Intestinal Glucose Absorption and GLP-1 in Mice

JACKY LI, ROGER W. XU, Jiaojuan He, Pablo Lapuerta

Background and Aims: YG1699, a dual inhibitor of SGLT1 and SGLT2, recently showed greater glucose reduction than dapagliflozin in patients with type 1 diabetes. This study examined whether YG1699 provides gastrointestinal SGLT1 inhibition. Materials and Methods: Male BALB/c mice (n=105) were randomly …

A phase 1 clinical trial of DB-020 intratympanic injections administered prior to high dose cisplatin chemotherapy to reduce ototoxicity.

Danny Rischin, Stephen John O’Leary, Christopher David Hart, Chandra Sai Diwakarla et autres

6043 Background: Hearing loss with cisplatin (CP) chemotherapy is common. DB-020 is a formulation of thiosulfate for intratympanic (IT) injection being developed to reduce CP ototoxicity. The primary objective of this Phase 1 study was to evaluate the safety and tolerability of …

au, us (code pays fourni par la source)

Telotristat ethyl reverses myxomatous changes in mice mitral valves

Xinmei Wang, Danielle Kuban-Johnston, Pablo Lapuerta, Carla M. R. Lacerda

Rationale Myxomatous mitral valve degeneration is a common pathological manifestation of mitral valve regurgitation, with or without valvular prolapse. In addition to similarities between naturally occurring and serotonergic valve degeneration, an increasing body of evidence has recently suggested that serotonin signaling is …

cn, us (code pays fourni par la source)